Pharmaceuticals

Global Egrifta Market 2026 expanding with metabolic disorder treatments

March 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Egrifta (Tesamorelin Acetate) Market Over The 2026–2030 Period?

The expansion observed in the past was largely due to an increase in cases of hiv-associated lipodystrophy, the side effects associated with long-term antiretroviral therapy, the clinical validation of GHRH analogs, a heightened awareness of the dangers of visceral fat, and an ongoing demand for specific abdominal fat reduction.

During the projection period, the anticipated growth is driven by several factors, including the advancement of individualized HIV treatment, the expanding development of peptide-based medicines, the more frequent identification of metabolic complications, favorable financial coverage for specialized medications, and a greater emphasis on the sustained well-being of individuals with HIV.

Key developments expected within the forecast timeframe encompass the emergence of extended-duration peptide treatments, tailored therapies for lipodystrophy, a broadening of applications for metabolic conditions, injectable treatments designed with the patient in mind, and the increased uptake of specialized biological drugs.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20043&type=smp

What Drivers Are Expected To Influence The Egrifta (Tesamorelin Acetate) Market During The Forecast Period?

The future expansion of the egrifta (tesamorelin acetate) market is significantly propelled by the growing incidence of human immunodeficiency virus (HIV) cases. These cases denote individuals infected with HIV, leading to a progressive weakening of their immune systems. A contributing factor to the escalation of HIV includes inadequate public awareness and education regarding preventative strategies, such as consistent condom use and routine testing, especially within vulnerable communities. Egrifta operates by stimulating growth hormone release, thereby aiding in the reduction of surplus visceral fat and enhancing body composition, which ultimately improves the general health and life quality for those living with HIV. An illustrative example comes from May 2024, when the Minnesota Department of Health, a US-based state health agency, disclosed that in 2023, MDH recorded 324 new HIV diagnoses, representing a 24% rise from 2022. Consequently, the expanding occurrence of human immunodeficiency virus (HIV) cases is fueling the growth of the egrifta (tesamorelin acetate) market.

How Is The Egrifta (Tesamorelin Acetate) Market Segmented Across Key Categories?

The egrifta (tesamorelin acetate) market covered in this report is segmented –

1) By Clinical Indication: Human Immunodeficiency Virus (HIV)-Associated Lipodystrophy, Growth Hormone Deficiency, Abdominal Obesity, Metabolic Syndrome

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

3) By End-Users: Hospitals, Specialized Clinics, Home Care

Which Upcoming Trends Are Expected To Influence The Egrifta (Tesamorelin Acetate) Market?

The egrifta (tesamorelin acetate) market is significantly characterized by the development of sophisticated synthetic peptide drugs, aiming to improve treatment efficacy for HIV-related lipodystrophy. Synthetic peptide drugs are artificially formulated compounds designed to achieve specific therapeutic outcomes by imitating or augmenting the actions of naturally occurring peptides. For instance, in December 2024, Theratechnologies Inc., a biopharmaceutical company based in Canada, announced the resumption of EGRIFTA SV production following a voluntary temporary halt at its contract manufacturer’s facility due to observations from an FDA inspection. A newly produced batch has successfully passed quality control and is set for release upon approval of a prior approval supplement by the US Food and Drug Administration (FDA), with two more batches currently in production. The company is strategically managing its stock to meet patient requirements until mid-January 2025 and is collaborating with the FDA to avoid any shortages in 2025. EGRIFTA SV is distributed solely within the United States.

Who Are The Dominant Players Shaping The Egrifta (Tesamorelin Acetate) Market Landscape?

Major companies operating in the egrifta (tesamorelin acetate) market are Theratechnologies Inc.

Read the full egrifta (tesamorelin acetate) market report here:

https://www.thebusinessresearchcompany.com/report/egrifta-tesamorelin-acetate-global-market-report

Which Region Is Forecast To Lead The Egrifta (Tesamorelin Acetate) Market In Terms Of Market Size?

North America was the largest region in the egrifta (tesamorelin acetate) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the egrifta (tesamorelin acetate) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Egrifta (Tesamorelin Acetate) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20043&type=smp

Browse Through More Reports Similar to the Global Egrifta (Tesamorelin Acetate) Market 2026, By The Business Research Company

Ethyl Acetate Market Report 2026

https://www.thebusinessresearchcompany.com/report/ethyl-acetate-global-market-report

Ethylene Vinyl Acetate Market Report 2026

https://www.thebusinessresearchcompany.com/report/ethylene-vinyl-acetate-global-market-report

Ecoa Esource And Clinical Trials Market Report 2026

https://www.thebusinessresearchcompany.com/report/ecoa-esource-and-clinical-trials-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795